Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2025-08-22 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
2024年度向特定对象发行股票证券募集说明书（申报稿）
Capital/Financing Update Classification · 95% confidence The document is titled "2024 年度向特定对象发行 A 股股票募集说明书" which translates to "2024 Annual Private Placement of A Shares Prospectus". It is issued by Shenzhen Microchip Biotechnology Co., Ltd. The text includes detailed information about the issuance of A shares to specific investors, including the issuance plan, pricing, number of shares, use of proceeds, risk factors, and regulatory approvals required from the China Securities Regulatory Commission (CSRC) and Shanghai Stock Exchange (SSE). The document is a comprehensive prospectus related to a capital raising event through a private placement of shares. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is lengthy (15,000 characters) and contains substantive details about the financing, not just an announcement or summary. Therefore, the appropriate classification is CAP with high confidence.
2025-08-22 Chinese
国投证券股份有限公司关于深圳微芯生物科技股份有限公司向特定对象发行股票之发行保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as an "发行保荐书" which translates to an "Issuance Sponsorship Letter" or "Sponsorship Document" related to a specific stock issuance by Shenzhen Chipscreen Biosciences Co., Ltd. It details the underwriting and sponsorship of a 2024 specific object issuance of A shares, including legal compliance, due diligence, internal approvals, shareholder meetings, financial data, and risk disclosures. The document is comprehensive and lengthy (15,000 characters), containing detailed financial data, shareholder structure, and regulatory compliance information. It is not a typical annual report or earnings release but rather a formal underwriting and sponsorship document related to a capital raising event. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is not a mere announcement or a proxy statement, but a detailed sponsorship report for a specific share issuance. Therefore, the correct classification is CAP with high confidence.
2025-08-22 Chinese
毕马威华振会计师事务所 (特殊普通合伙)关于深圳微芯生物科技股份有限公司向特定对象发行股票的财务报告及审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" (Audit Report) for the fiscal year 2024 of Shenzhen Microcore Biotechnology Co., Ltd. It contains detailed auditor opinions, audit basis, key audit matters, management responsibilities, and extensive accounting policies and estimates. The content includes audit procedures, financial statement references, and compliance with Chinese accounting standards and regulatory requirements. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. It is clearly a standalone audit report, not an annual report or other filing type. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2024
2025-08-22 Chinese
上海市通力律师事务所关于深圳微芯生物科技股份有限公司向特定对象发行股票之法律意见书
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter issued by a law firm regarding Shenzhen Microchip Biotechnology Co., Ltd.'s 2024 private placement of shares (向特定对象发行股票). It includes extensive legal analysis, approvals, authorizations, and compliance with relevant laws and regulations concerning the issuance of A shares to specific investors. The document references the issuance process, shareholder meetings, board resolutions, pricing, lock-up periods, and use of proceeds. It is a legal opinion related to a capital raising event, specifically a private placement of shares. This fits the category of Capital/Financing Update (CAP), as it provides detailed legal and procedural information about the company's financing activity. The document is not an announcement of a report, nor a full annual or interim report, nor a proxy or voting result. It is a legal opinion letter supporting a capital issuance.
2025-08-22 Chinese
国投证券股份有限公司关于深圳微芯生物科技股份有限公司向特定对象发行股票之上市保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as a "上市保荐书" which translates to "Listing Sponsorship Letter" or "Sponsorship Document for Stock Listing." It is issued by a securities company (国投证券股份有限公司) acting as the sponsor for Shenzhen Chipscreen Biosciences Co., Ltd. regarding its 2024 specific object issuance of A shares. The document contains detailed information about the issuer, its business, products, financial data, and the issuance plan. It references regulatory frameworks related to securities issuance and listing on the Shanghai Stock Exchange. This type of document is a formal sponsorship and underwriting document required for a company's stock issuance and listing process, which is a capital market activity related to financing and issuance of shares. It is not an annual report, earnings release, or management report. It is not a proxy, voting result, or governance document. It is not a transcript or audit report. It is a detailed capital/financing update related to a specific share issuance and listing. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2025-08-22 Chinese
关于2024年度向特定对象发行A股股票申请获得上海证券交易所受理的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (581 characters) regarding the acceptance by the Shanghai Stock Exchange of the company's application for a specific issuance of A shares. It mentions the regulatory review process and the need for further approvals before implementation. There is no detailed financial data or report content, only a notice of acceptance and ongoing regulatory process. This fits the definition of a Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes.
2025-08-22 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.